This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
4o91
From Proteopedia
| Line 1: | Line 1: | ||
| - | ''' | + | ==Crystal Structure of type II inhibitor NG25 bound to TAK1-TAB1== |
| - | + | <StructureSection load='4o91' size='340' side='right' caption='[[4o91]], [[Resolution|resolution]] 2.39Å' scene=''> | |
| - | + | == Structural highlights == | |
| - | + | <table><tr><td colspan='2'>[[4o91]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4O91 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4O91 FirstGlance]. <br> | |
| - | + | </td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NG2:N-{4-[(4-ETHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}-4-METHYL-3-(1H-PYRROLO[2,3-B]PYRIDIN-4-YLOXY)BENZAMIDE'>NG2</scene><br> | |
| - | + | <tr><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Mitogen-activated_protein_kinase_kinase_kinase Mitogen-activated protein kinase kinase kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.25 2.7.11.25] </span></td></tr> | |
| - | + | <tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4o91 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4o91 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4o91 RCSB], [http://www.ebi.ac.uk/pdbsum/4o91 PDBsum]</span></td></tr> | |
| + | <table> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Mitogen-activated protein kinase kinase kinase]] | ||
| + | [[Category: Gurbani, D.]] | ||
| + | [[Category: Hunter, J C.]] | ||
| + | [[Category: Tan, L.]] | ||
| + | [[Category: Westover, K D.]] | ||
| + | [[Category: Mitogen-activated protein kinase kinase kinase 7]] | ||
| + | [[Category: Serine/threonine kinase which acts as an essential component of the map kinase signal transduction pathway]] | ||
| + | [[Category: Tgf-beta-activated kinase 1 and map3k7-binding protein 1]] | ||
| + | [[Category: Tgf-beta-activated kinase 1 and map3k7-binding protein 1 chimera]] | ||
| + | [[Category: Transferase-transferase inhibitor complex]] | ||
Revision as of 07:48, 30 July 2014
Crystal Structure of type II inhibitor NG25 bound to TAK1-TAB1
| |||||||||||
Categories: Mitogen-activated protein kinase kinase kinase | Gurbani, D. | Hunter, J C. | Tan, L. | Westover, K D. | Mitogen-activated protein kinase kinase kinase 7 | Serine/threonine kinase which acts as an essential component of the map kinase signal transduction pathway | Tgf-beta-activated kinase 1 and map3k7-binding protein 1 | Tgf-beta-activated kinase 1 and map3k7-binding protein 1 chimera | Transferase-transferase inhibitor complex
